Tesofensine has one of the most eye-catching numbers in obesity pharmacology — and one of the biggest asterisks. A single Phase II trial reported weight loss roughly double what the first generation of approved obesity drugs achieved, which is why it keeps resurfacing in “next big thing” coverage. But the evidence behind that number is thinner and more complicated than the headline suggests, and honesty about both halves is the point of this monograph.
What it is (and what it isn’t)
First, a clarification that matters: tesofensine is not a peptide. It is a small-molecule triple monoamine reuptake inhibitor — it blocks the presynaptic reuptake of noradrenaline, dopamine and serotonin, raising the levels of all three in the brain.[1] That mechanism puts it closer to a stimulant/antidepressant class than to the peptide therapeutics elsewhere on this site. It was originally developed (as NS2330) for Alzheimer’s and Parkinson’s disease; weight loss showed up as a side effect in those neurodegeneration programs, and the drug was repurposed toward obesity.[3]
The headline trial: TIPO-1
The number everyone cites comes from TIPO-1, a Phase II randomized, double-blind, placebo-controlled trial in 203 obese adults across five Danish centers, run over 24 weeks on top of an energy-restricted diet.[1] The weight loss was dose-dependent and, at the higher doses, large:
- Diet + placebo2%
- Tesofensine 0.25 mg4.5%
- Tesofensine 0.5 mg9.2%
- Tesofensine 1.0 mg10.6%
At the 0.5 mg dose — the one usually proposed for development — mean weight loss was 9.2% versus 2.0% on diet and placebo; the 1.0 mg dose reached 10.6% but with more side effects.[1] On its face, that is a very strong Phase II signal. The trouble is what came after.
What happened next: a completed Phase III, but still no approval
Tesofensine did not go on to a US or EU Phase III program. A Phase III registration trial for standalone tesofensine was completed — run by Saniona’s commercial partner Medix in 372 adults with obesity in Mexico — and in 2018 both studied doses (0.25 mg and 0.5 mg) were reported to meet their primary and secondary weight-loss endpoints against placebo.[5] That trial was never published in a peer-reviewed journal, and it has not converted into approval: Mexico’s regulator, Cofepris, issued only a non-binding favorable opinion in 2023, and as of the most recent public update Medix had still not received full marketing authorization.[6] No Phase III trial has been completed for the US or EU market, and tesofensine remains unapproved by the FDA. Separately, the most recent published randomized human data is for Tesomet, a combination of tesofensine with the beta-blocker metoprolol, tested in a small trial (n=21) in the niche condition of hypothalamic obesity — where it produced about 6.3% additional weight loss over 24 weeks.[4] The metoprolol was added specifically to blunt tesofensine’s cardiovascular effects, which points to the safety issue below. Recent 2024–25 tesofensine research exists, but it is in rodents, not people — not human obesity evidence.
The safety signal: it’s a stimulant
Tesofensine behaves like the monoamine-raising drug it is. In TIPO-1 the most common adverse effects were dry mouth, nausea, constipation, hard stools, diarrhea and insomnia, and while blood pressure did not rise significantly at the lower doses, heart rate increased by 7.4 beats per minute at the 0.5 mg dose.[1] A raised heart rate is exactly the kind of cardiovascular signal that has sunk other centrally-acting appetite drugs, and it is why the later Tesomet program paired the drug with a beta-blocker. This is not a benign supplement-style compound.
Where it sits versus the approved options
It is tempting to line tesofensine’s 9.2% up against the GLP-1 drugs, but that is not a fair comparison: semaglutide and tirzepatide have multiple large Phase III trials and FDA approval, while tesofensine has one flagged Phase II trial and no approval. If you want a molecule with a similar weight-loss ambition but a real outcome record, the honest place to look is the approved incretins — compare them in our GLP-1 comparison tool and our roundup of peptides marketed for weight loss. For another metabolic compound running almost entirely on preclinical promise, see 5-Amino-1MQ.
The honest bottom line
Tesofensine is a genuinely interesting drug with a genuinely unsettled record. Its triple-monoamine mechanism produced a striking Phase II weight-loss result — but that result carries a journal Expression of Concern, and even the Phase III registration trial that did complete (in Mexico, never peer-reviewed) has not converted into approval anywhere; it comes with a stimulant-type cardiovascular profile.[1][2] It is investigational, unapproved, and a long way from the evidence base of the drugs people can actually be prescribed. Treat the 9.2% as a promising but flagged signal, not a proven outcome — and treat anyone selling tesofensine today as operating well ahead of the science. Because it has never been approved, there is also no legitimate market price for it; we explain what the figures circulating as tesofensine’s cost actually represent, and what you can price instead.
